NO20053792L - Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander - Google Patents

Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander

Info

Publication number
NO20053792L
NO20053792L NO20053792A NO20053792A NO20053792L NO 20053792 L NO20053792 L NO 20053792L NO 20053792 A NO20053792 A NO 20053792A NO 20053792 A NO20053792 A NO 20053792A NO 20053792 L NO20053792 L NO 20053792L
Authority
NO
Norway
Prior art keywords
sulfonylindazoles
heterocycly
hydroxytryptamine
ligands
receptor
Prior art date
Application number
NO20053792A
Other languages
English (en)
Norwegian (no)
Inventor
Albert J Robichaud
Ronald Charles Bernotas
Yinfa Yan
Guangcheng Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20053792L publication Critical patent/NO20053792L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20053792A 2003-02-14 2005-08-10 Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander NO20053792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44761303P 2003-02-14 2003-02-14
PCT/US2004/003926 WO2004074243A2 (en) 2003-02-14 2004-02-10 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
NO20053792L true NO20053792L (no) 2005-08-10

Family

ID=32908471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053792A NO20053792L (no) 2003-02-14 2005-08-10 Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander

Country Status (21)

Country Link
US (3) US7238696B2 (es)
EP (1) EP1592683A2 (es)
JP (1) JP2006518385A (es)
KR (1) KR20050101551A (es)
CN (1) CN100422171C (es)
AR (1) AR043181A1 (es)
AU (1) AU2004213374A1 (es)
BR (1) BRPI0407253A (es)
CA (1) CA2515570A1 (es)
CO (1) CO5650164A2 (es)
CR (1) CR7930A (es)
EC (1) ECSP055964A (es)
MX (1) MXPA05008438A (es)
NO (1) NO20053792L (es)
NZ (1) NZ541699A (es)
PL (1) PL378120A1 (es)
RU (1) RU2347780C2 (es)
TW (1) TW200505904A (es)
UA (1) UA80184C2 (es)
WO (1) WO2004074243A2 (es)
ZA (1) ZA200506416B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200301142A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
IL158448A0 (en) * 2001-04-20 2004-05-12 Wyeth Corp Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CN101291913A (zh) * 2005-08-15 2008-10-22 惠氏公司 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
KR20090006148A (ko) * 2006-04-05 2009-01-14 와이어쓰 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
WO2007147883A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
EP2158195A1 (en) 2007-05-15 2010-03-03 Wyeth LLC 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009155399A1 (en) * 2008-06-20 2009-12-23 Wyeth 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2010124042A2 (en) * 2009-04-23 2010-10-28 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
CN104693186B (zh) * 2014-12-31 2017-12-22 青岛黄海制药有限责任公司 一种吲哚衍生物中c‑f键生成c‑n键合成西泮类药物的方法
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CA3187566A1 (en) 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
CA3243547A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS
US12098144B2 (en) 2021-12-21 2024-09-24 Corcept Therapeutics Incorporated Piperazine indazole glucocorticoid receptor antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
AR008245A1 (es) * 1996-06-21 1999-12-29 Glaxo Group Ltd Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
PL340753A1 (en) 1997-11-04 2001-02-26 Pfizer Prod Inc Substitution of indazolic bioisoster for cathechol in therapeutically active compounds
BR0115102B1 (pt) 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
BR0116323A (pt) 2000-12-22 2003-10-14 Wyeth Corp Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
MXPA03005433A (es) 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilalquilindol o-azaindol como ligandos de 5-hidroxitriptamina-6.
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL158448A0 (en) 2001-04-20 2004-05-12 Wyeth Corp Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EA200301142A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
JP2005527463A (ja) 2001-08-07 2005-09-15 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
WO2003080608A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
CA2515571A1 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE102004046356A1 (de) * 2004-09-24 2006-03-30 Clariant Gmbh Verfahren zur Herstellung von Alk(en)ylphosphorsäureestersalzen

Also Published As

Publication number Publication date
WO2004074243A2 (en) 2004-09-02
PL378120A1 (pl) 2006-03-06
RU2347780C2 (ru) 2009-02-27
US20090253711A1 (en) 2009-10-08
CN1771244A (zh) 2006-05-10
AR043181A1 (es) 2005-07-20
CO5650164A2 (es) 2006-06-30
UA80184C2 (en) 2007-08-27
BRPI0407253A (pt) 2006-01-31
EP1592683A2 (en) 2005-11-09
ECSP055964A (es) 2006-01-16
RU2005128556A (ru) 2006-01-27
MXPA05008438A (es) 2005-10-19
CN100422171C (zh) 2008-10-01
ZA200506416B (en) 2007-02-28
CR7930A (es) 2006-02-07
JP2006518385A (ja) 2006-08-10
US20040167122A1 (en) 2004-08-26
NZ541699A (en) 2009-01-31
CA2515570A1 (en) 2004-09-02
TW200505904A (en) 2005-02-16
WO2004074243A3 (en) 2004-12-02
US7560470B2 (en) 2009-07-14
AU2004213374A1 (en) 2004-09-02
US20070232618A1 (en) 2007-10-04
KR20050101551A (ko) 2005-10-24
US7238696B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
NO20060230L (no) Nye aminobenzofenonforbindelser
NO20044764L (no) 1-(aminoalkyl)-3-sulfonylindol og -indazolderivater som 5-hydroksytryptamin-6 ligander
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20055731L (no) Cannabinoide reseptorligander og deres anvendelse
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
WO2002051837A3 (en) Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20063787L (no) Terapeutiske preparater
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
BRPI0410905A (pt) inibidores de p-38
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
NO20063449L (no) Substituerte heterocykler og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application